In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis
| Autor: | Francesca Falconi-Agapito, Faten Bel Haj Rhouma, Maria Cruz, Mehdi Chenik, Himanshu Kaushal, Narender Singh Negi, Pilar Torres, Wafa Markikou-Ouni, Angela Privat, Rym Chamakh-Ayari, Amel Meddeb-Garnaoui, Eugenia Carrillo, Poonam Salotra, Julie Pagniez, Narges Bahi-Jaber, Rachel Bras-Gonçalves, Javier Moreno, Karim Aoun, Gérard-Marie Papierok, Jorge Arevalo, Jean-Loup Lemesre, Elodie Petitdidier |
|---|---|
| Přispěvatelé: | Unión Europea. Comisión Europea. 7 Programa Marco, Laboratoire de Parasitologie Médicale, Biotechnologies et Biomolécules (LR11IPT06), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Interactions hôtes-vecteurs-parasites-environnement dans les maladies tropicales négligées dues aux trypanosomatides (UMR INTERTRYP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université de Bordeaux (UB), Laboratoire de Transmission, Contrôle et Immunobiologie des Infections - Laboratory of Transmission, Control and Immunobiology of Infection (LR11IPT02), Expression de Gènes et régulation Epigénétique par l'ALiment (EGEAL), Institut Polytechnique LaSalle Beauvais, WHO Collaborating Center for Leishmaniasis, Centro Nacional de Microbiologia, Instituto de Salud Carlos III [Madrid] (ISC), National Institute of Pathology (ICMR), Safdarjung Hospital Campus, Instituto de Medicina Tropical 'Alexander von Humboldt' (IMT AvH), Universidad Peruana Cayetano Heredia (UPCH), BVT-VIRBAC, La Seyne sur Mer, France, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain, This study received financial support from EU’s Seventh Framework Programme (FP7) (RAPSODI project, grant agreement number 223341). URL offunder’s website: http://cordis.europa.eu/fp7/home_en.html), European Project: 36197,RAPSODI, Université de Bordeaux (UB)-Institut de Recherche pour le Développement (IRD)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad) |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Protozoan Vaccines
Granzyme B production [SDV]Life Sciences [q-bio] Protozoology Adaptive Immunity PHENOTYPE Granzymes Mice 0302 clinical medicine Zoonoses Medicine and Health Sciences TECHNIQUE PCR Leishmania major Immune Response Leishmaniasis ANALYSE STATISTIQUE Protozoans Leishmania Vaccines EXPERIMENTATION IN VITRO 0303 health sciences Multidisciplinary Interleukin-10/blood biology Granzymes/blood Acquired immune system Vaccination and Immunization Interleukin-10 3. Good health Infectious Diseases Phenotype Veterinary Diseases Leishmaniasis/blood/immunology/prevention & control Antigens Surface Cytokines VACCINATION Medicine Leishmania infantum Research Article Biotechnology Neglected Tropical Diseases ANTICORPS Tumor Necrosis Factor-alpha/blood ANTIGENE Antigens Protozoan/biosynthesis/chemistry/immunology Science Immunology 030231 tropical medicine Leishmania donovani Antigens Protozoan Microbiology Leishmania/immunology Interferon-gamma 03 medical and health sciences Immune system Cutaneous leishmaniasis Antigen LEISHMANIOSE EVALUATION TEST ELISA Vaccine Development PROTEINE Parasitic Diseases ETUDE COMPARATIVE medicine Animals Humans [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology purl.org/pe-repo/ocde/ford#1.06.01 [https] Protozoan Vaccines/biosynthesis/chemistry/immunology IMMUNITE 030304 developmental biology Tumor Necrosis Factor-alpha Antigens Surface/biosynthesis/chemistry/immunology Immunity Organisms Biology and Life Sciences CYTOMETRIE Molecular Development Tropical Diseases biology.organism_classification medicine.disease Parasitic Protozoans Immunity Humoral Solubility Immune System Humoral Immunity ETUDE EXPERIMENTALE Clinical Immunology Veterinary Science [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology Interferon-gamma/blood Developmental Biology |
| Zdroj: | PLoS ONE, Vol 9, Iss 5, p e92708 (2014) PLoS ONE PLoS ONE, 2014, 9 (5), pp.e92708. ⟨10.1371/journal.pone.0092708⟩ PLoS ONE, Public Library of Science, 2014, 9 (5), pp.e92708. ⟨10.1371/journal.pone.0092708⟩ Repisalud Instituto de Salud Carlos III (ISCIII) |
| ISSN: | 1932-6203 |
| Popis: | PSA (Promastigote Surface Antigen) belongs to a family of membrane-bound and secreted proteins present in several Leishmania (L.) species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice. We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S) produced in a L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm) or L. braziliensis (CCLb) or visceral leishmaniasis due to L. donovani (CVLd) and in healthy individuals. Healthy individuals were subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum infection) or non immune/naive individuals (HLR: Healthy Low Responders), depending on whether they produce high or low levels of IFN-γ in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-γ, granzyme B and IL-10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-α in more. No significant cytokine response was observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase in CD4+ T cells producing IFN-γ after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the percentage of IFN-γ-producing CD4+ T cells and the released IFN-γ. We showed that the LaPSA-38S protein was able to induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection. This study received financial support from EU's Seventh Framework Programme (FP7) (RAPSODI project, grant agreement number 223341). Sí |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|